by Naz Dana | Aug 23, 2018 | Business |
Last spring, we started a new series of blog posts introducing Perlara team members – from new hires, to not-so-new hires and, in our last post, a long-time Perlara team member. Our goal has been to spotlight the Perlara scientists who may not have started out in the...
by Feba Sam | Jul 10, 2018 | Science |
At Perlara, we work to find therapeutics for rare genetic diseases. We develop and use immunoassays, phase contrast imaging, as well as enzymatic assays, in order to screen thousands of compounds and obtain hits from cell readouts to complement our model organism...
by Sangeetha Iyer | Jul 9, 2018 | Science |
Perlara’s worm team recently attended two C. elegans neuroscience conferences – CE Neuro 2018 & CE Aging 2018 – both held at the University of Wisconsin, Madison. This post recaps Zach and my time at the CE Neuro 2018 conference, which focused on...
by Julide Bilen | Jun 7, 2018 | PMM2-CDG |
An update on the development of PMM2 Drosophila models, and our work to design high throughput drug screen for PMM2 deficiency — Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common type of congenital disorder of glycosylation resulting from a defect in...
by Jessica Lao | May 8, 2018 | PMM2-CDG |
Drug repurposing screen in haploid PMM2-CDG yeast models During Stage 1 of our PerlQuest partnership with Maggie’s Cure, we generated haploid PMM2-CDG yeast models of three pathogenic variants: F119L, R141H, and V231M. We expressed these variants in the yeast...
